Celldex Therapeutics Inc. (CLDX)
19.31
0.37 (1.95%)
At close: Apr 22, 2025, 3:59 PM
1.95% (1D)
| Bid | 17.6 |
| Market Cap | 1.28B |
| Revenue (ttm) | 7.02M |
| Net Income (ttm) | -157.86M |
| EPS (ttm) | -2.45 |
| PE Ratio (ttm) | -7.88 |
| Forward PE | -4.82 |
| Analyst | Buy |
| Ask | 24 |
| Volume | 385,822 |
| Avg. Volume (20D) | 935,904.6 |
| Open | 19.15 |
| Previous Close | 18.94 |
| Day's Range | 18.93 - 19.39 |
| 52-Week Range | 14.40 - 47.00 |
| Beta | 1.59 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity...
Industry Biotechnology
Sector Healthcare
IPO Date May 15, 1986
Employees 186
Stock Exchange NASDAQ
Ticker Symbol CLDX
Website https://www.celldex.com
Analyst Forecast
According to 8 analyst ratings, the average rating for CLDX stock is "Buy." The 12-month stock price forecast is $46, which is an increase of 138.22% from the latest price.
Stock ForecastsNext Earnings Release
Celldex Therapeutics Inc. is scheduled to release its earnings on May 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
7 months ago
-12.06%
Celldex Therapeutics shares are trading lower. The...
Unlock content with
Pro Subscription
8 months ago
-8.45%
Celldex Therapeutics shares are trading lower. The company announced topline results from its Phase 2 clinical trial of barzolvolimab.
